International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

IPC Statement on SARS-CoV-2 Vaccines and Psoriasis

The SARS-CoV-2 pandemic continues to have a considerable impact on the provision of appropriate care to people with psoriasis. In many countries there is currently great excitement about the potential initiation of vaccination programs to people at risk and the general population. While this news is to be welcomed, the impact of psoriasis therapy, particularly systemic therapy, on the effectiveness and safety of vaccines needs to be considered.

The International Psoriasis Council (IPC) advises physicians and other healthcare practitioners to take into account the following:

The principal considerations for SARS-CoV-2 vaccines are the same as for any vaccine: Avoid live-attenuated vaccines if receiving an immunosuppressive/immunomodulatory medication and be aware that the effectiveness of vaccination may be attenuated in people taking drugs that affect the immune system.

Visit the W.H.O. website to learn more about the current COVID-19 vaccines.

We anticipate that most patients with psoriasis who do not have a contraindication or a known allergy to a vaccine component will be recommended to receive one of these SARS-CoV-2 vaccines as soon as possible based on local availability and guidance from local public health bodies.

Trials to date have not included people taking drugs that affect the immune system and thus the effects of the vaccines in this specific population will need to be established.

Many people with psoriasis have raised concerns about potential adverse effects of vaccines on their skin disease. However, there is no evidence that vaccines affect psoriasis onset or severity. Registry data is being collected to inform whether SARS-Cov-2 vaccines either positively or negatively affect psoriasis outcomes. You can learn more by visiting the PsoProtect registry.

It is important that all people with psoriasis have access to adequate care. This includes access to SARS-CoV-2 vaccines.

The IPC will continue to provide updates to the global dermatology community as we learn more about SARS-CoV-2, vaccines and their impact on psoriasis. For the most recent information from the psoriasis community, click here.

Recent Posts
BIOMAP Collaboration Update A Systemic Review on Biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

BMS Press Release Graphic

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Blog - Commentary - Alexander Egeberg - graphic

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Also Read


New IPC Councilor

Dr. Claus Johansen joins the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.

Read More

PsoProtect Registry Data Update

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.